GH Research PLC Dossier
Qualitative Analysis
Business overview
GH Research PLC (NASDAQ: GHRS) is a Dublin, Ireland-based clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company's primary focus is on developing novel, proprietary mebufotenin (5-MeO-DMT) therapies designed for ultra-rapid and durable remission in patients suffering from Treatment-Resistant Depression (TRD). Its lead product candidate, GH001, is an inhalable mebufotenin formulation administered via a proprietary inhalation approach. Additionally, the company is developing GH002, an intravenous mebufotenin formulation, and GH003, an intranasal formulation, both of which are in earlier stages of clinical development.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead mebufotenin candidate, GH001, toward a global Phase 3 pivotal program in treatment-resistant depression (TRD). This includes bridging clinical data to a proprietary aerosol delivery device and seeking regulatory alignment with the FDA.
Expected impact: Aims to replicate the strong Phase 2b efficacy results (placebo-adjusted MADRS reduction of -15.5 points) in a larger, global patient population to support regulatory approval.
Evaluating and transitioning to a proprietary aerosol delivery device for the administration of GH001. This was supported by the Phase 1 clinical pharmacology trial (GH001-HV-106) in healthy volunteers to bridge from the commercially available device used in earlier trials.
Expected impact: Secures proprietary device-drug combination rights, enhancing intellectual property protection and optimizing clinical delivery.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations